Stock comparison
Jazz Pharmaceuticals
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
JAZZ
Jazz Pharmaceuticals
Market cap
$15.05B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | JAZZ | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 46D | 69B | MTD |
| Benjamin Graham | 58D | 65B | MTD |
| Philip Fisher | 42D | 63C | MTD |
| Peter Lynch | 36D | 66B | MTD |
| Joel Greenblatt | 44D | 68B | MTD |
| Charlie Munger | 42D | 74B | MTD |
| Terry Smith | 35D | 70B | MTD |
Side-by-side metrics
| Metric | JAZZ | MTD |
|---|---|---|
| Market cap | $15.05B | $22.29B |
| P/E (TTM) | 501.8x | 25.3x |
| EV/EBIT | 82.8x | 21.6x |
| ROIC (TTM) | -0.62% | 36.09% |
| Gross margin | 84.12% | 57.79% |
| Net margin | 0.66% | 21.4% |
| Revenue CAGR 5y | 8.37% | 2.01% |
| EPS CAGR 5y | - | 6.12% |
| Debt / Equity | 1.2x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
JAZZ leads on
- Revenue CAGR 5y8.37%vs 2.01%+76%
- Gross margin84.12%vs 57.79%+31%
MTD leads on
- Debt / Equity-vs 1.2x+102%
- ROIC (TTM)36.09%vs -0.62%+102%
- Net margin21.4%vs 0.66%+97%
- P/E (TTM)25.3xvs 501.8x+95%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.